isoproterenol has been researched along with syringic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, K; Mateen, S; Moin, S; Naeem, SS; Rizvi, W; Shahzad, S | 1 |
| Al Omar, SY; E, MP; Kodidhela, LD; Mohammad, A; S, M; Shaik, AH | 1 |
| Bai, L; Han, X; Jeong, MH; Kee, HJ | 1 |
3 other study(ies) available for isoproterenol and syringic acid
| Article | Year |
|---|---|
Syringic acid protects from isoproterenol induced cardiotoxicity in rats.
Topics: Adenosine Triphosphatases; Animals; Biomarkers; Biphenyl Compounds; Body Weight; Cardiotoxicity; Cytoprotection; Erythrocytes; Fibrosis; Gallic Acid; Glutathione; Heart; Isoproterenol; Male; Myocardium; Nitric Oxide; Organ Size; Oxidative Stress; Picrates; Rats; Rats, Wistar | 2019 |
Combined cardio-protective ability of syringic acid and resveratrol against isoproterenol induced cardio-toxicity in rats via attenuating NF-kB and TNF-α pathways.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Gallic Acid; Isoproterenol; Male; NF-kappa B; Rats; Rats, Wistar; Resveratrol; Signal Transduction; Tumor Necrosis Factor-alpha | 2020 |
Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg.
Topics: Animals; Cardiomegaly; Fibrosis; Gallic Acid; Isoproterenol; Mice; Myocardium | 2022 |